Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their…
Read More »chemotherapy
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and…
Read More »